National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 7) (Cth)

PB 75 of 2021

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 7)

National Health Act 1953

___________________________________________________________________________

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated         27 July 2021

NIKOLAI TSYGANOV

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 7).

(2)This Instrument may also be cited as PB 75 of 2021.

1. Commencement

This Instrument commences on 1 August 2021.

1. Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1       Amendments

1. Schedule 1, after entry for Alendronic acid with colecalciferol and calcium

insert:

Alirocumab	Injection 75 mg in 1 mL single use pre-filled pen	20	2	5
Injection 150 mg in 1 mL single use pre-filled pen	20	2	5

1. Schedule 1, entry for Exenatide

omit:

Injection (modified release) 2 mg single dose pre‑filled pen 20 4 5

1. Schedule 1, after entry for Fosinopril with hydrochlorothiazide

insert:

Fremanezumab	Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe	20	1	2
20	1	5

1. Schedule 1, after entry for Riluzole

insert:

Risdiplam	Powder for oral solution 750 micrograms per mL, 80 mL	20	1	0
20	1	5